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Aims: Endothelial cell dysfunction drives the initiation and pathogenesis of pulmonary arterial 2 
hypertension (PAH). We aimed to characterise endothelial cell (EC) dynamics in PAH at 3 
single-cell resolution. 4 
Methods and Results: We carried out single-cell RNA sequencing (scRNA-seq) of lung ECs 5 
isolated from an EC lineage-tracing mouse model in Control and SU5416/Hypoxia-induced 6 
PAH conditions. EC populations corresponding to distinct lung vessel types, including two 7 
discrete capillary populations, were identified in both Control and PAH mice. Differential gene 8 
expression analysis revealed global PAH-induced EC changes that were confirmed by bulk 9 
RNA-seq. This included upregulation of the major histocompatibility complex class II 10 
pathway, supporting a role for ECs in the inflammatory response in PAH. We also identified a 11 
PAH response specific to the second capillary EC population including upregulation of genes 12 
involved in cell death, cell motility and angiogenesis. Interestingly, four genes with genetic 13 
variants associated with PAH were dysregulated in mouse ECs in PAH. To compare relevance 14 
across PAH models and species, we performed a detailed analysis of EC heterogeneity and 15 
response to PAH in rats and humans through whole-lung PAH scRNA-seq datasets, revealing 16 
that 51% of up-regulated mouse genes were also up-regulated in rat or human PAH. We 17 
identified promising new candidates to target endothelial dysfunction including CD74, the 18 
knockdown of which regulates EC proliferation and barrier integrity in vitro. Finally, with an 19 
in silico cell ordering approach, we identified zonation-dependent changes across the 20 
arteriovenous axis in mouse PAH and showed upregulation of the Serine/threonine-protein 21 
kinase Sgk1 at the junction between the macro- and micro-vasculature. 22 
Conclusions: This study uncovers PAH-induced EC transcriptomic changes at a high 23 













Translational perspective 27 
Pulmonary arterial hypertension (PAH) is a rare and progressive disease with substantial unmet 28 
clinical need. Despite well-established treatment regimes, PAH prognosis remains poor, 29 
leading to right heart failure and death. Endothelial cells play a crucial role in the primary 30 
vascular changes evident in PAH development and progression. Here, we dissect the mouse 31 
endothelial response to PAH at a single-cell resolution, and integrate human and rat genomic 32 
and transcriptomic datasets to identify genes and pathways relevant to pathogenesis. The 33 
identification of distinct molecular mechanisms and potential therapeutic targets is crucial for 34 
the future development of pharmacological interventions targeting endothelial dysfunction. 35 












Pulmonary arterial hypertension (PAH) is a rare (15-50 cases per million1) but progressive 38 
disease characterised by elevated pulmonary arterial pressure (mean >25 mmHg), and right 39 
ventricular hypertrophy2. While treatments to delay disease progression are available, PAH has 40 
a poor prognosis with eventual right heart failure and death2. Clinical subtypes include heritable 41 
PAH, with mutations most commonly found in the bone morphogenic protein receptor II 42 
(BMPR2) gene, and idiopathic PAH (IPAH)3. PAH pathogenesis is complex, involving 43 
pulmonary vessel remodelling, enhanced vasoconstriction, and inflammation affecting the 44 
arteries and microvasculature4. In humans and some mammals, PAH is also characterised by 45 
the presence of plexiform lesions in arterial branching points4. Animal models have been 46 
developed to study the pathogenesis of PAH. The widely used SuHx mouse model, which 47 
utilises Sugen 5416 (SU5416) injection and chronic hypoxia (10% O2), leads to increased right 48 
ventricular systolic pressure (RVSP) and right ventricular hypertrophy5, 6.  49 
Endothelial cells (ECs) are involved in the primary vascular changes leading to PAH7. 50 
Subsequent changes include smooth muscle hyperplasia and proliferation contributing to 51 
intima remodelling and the recruitment of inflammatory cells. Endothelial injury is common in 52 
vascular diseases such as atherosclerosis, peripheral disease8 and pulmonary hypertension9. In 53 
PAH, EC apoptosis has been observed in the early stages of the disease, while 54 
hyperproliferative apoptosis-resistant ECs may directly contribute to vessel remodelling in 55 
later stages7. Loss of endothelium barrier integrity, and altered autocrine and paracrine EC 56 
signalling in PAH lead to vasoconstrictor and vasodilator imbalance, and impaired recruitment 57 
and/or activation of other cell types10. ECs may also contribute to arterial remodelling via 58 












Transcriptomic changes in PAH have previously been investigated at the whole-organ and 61 
tissue level predominantly using microarray, identifying several genes associated with vascular 62 
remodelling and inflammation14. However, as different cell types contribute to PAH 63 
throughout its development, these global approaches may hinder the identification of novel 64 
targets for therapeutic development. Single-cell RNA-sequencing (scRNA-seq) has 65 
revolutionised the study of complex tissues in biological and pathological conditions15. In 66 
cardiovascular applications, scRNA-seq has improved our understanding of EC development 67 
and heterogeneity16-18, the characterisation of cell zonation19 and the identification of 68 
pathological cell populations 20. Recently, scRNA-seq was applied to whole-lung tissues from 69 
two different rat models of PAH21 and IPAH patient lung tissues22, revealing changes in the 70 
distinct pulmonary cell populations, including ECs21, 22. However, the whole-lung approach 71 
does not allow for the study of EC heterogeneity at a high resolution.  72 
Here, we utilised an endothelial lineage-tracing mouse to assess pulmonary EC responses to 73 
PAH with scRNA-seq. With a well-established mouse model of pulmonary hypertension which 74 
induces right ventricular hypertrophy and increased RVSP 5, 6, we elucidate the dynamic EC 75 
responses at a subpopulation level and across the arteriovenous axis. In addition, our dataset is 76 




Extended methods can be found in the online Supplementary Methods. 81 
 82 











All animal experiments were performed in accordance with the guidelines from Directive 84 
2010/63/EU of the European Parliament on the protection of animals used for scientific 85 
purposes and under the auspices of UK Home Office Project and Personal Licenses held within 86 
The University of Edinburgh facilities. Cdh5-CreERT2-TdTomato mice were generated by 87 
breeding Cdh5-CreERT2 with ROSA-TdTomato (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze) 88 
(JAX stock #00790923). To achieve induction of Cre, female Cdh5-CreERT2-TdTomato mice 89 
were gavaged with 400mg/kg of tamoxifen, followed by a two-week wash-out period. To 90 
induce PAH in Cdh5-CreERT2-TdTomato mice and C57/BL6 mice, female mice were treated 91 
with three weeks of weekly 20 mg/kg SU5416 injection, while exposed to chronic hypoxia 92 
(10% oxygen) as previously described24, 25. At the end of the procedure, right ventricular 93 
systolic pressure (RVSP) was measured under terminal anaesthesia (4% isoflurane) and the 94 
mice were euthanised by exsanguination. 95 
scRNA-seq sample preparation and analysis: 96 
TdTomato+ mouse lung cells were isolated and sorted as previously described26. ScRNA-seq 97 
libraries were prepared using the Single Cell 3′ Reagent Kit User Guide v2 (10x Genomics). 98 
Libraries were sequenced on NovaSeq S2 at Edinburgh Genomics. Read mapping and 99 
generation of the expression matrix were done with CellRanger using a custom annotation 100 
containing the transcript sequence of TdTomato. Low-quality cells were removed using 101 
Scater27. The data was normalised using batchelor28. Dimensionality reduction, cluster 102 
identification on “merged” or “integrated” data, and differential gene expression analysis were 103 
performed with Seurat29. SingleR was used for cell annotation30. KEGG Pathway and Gene 104 
Ontology analysis and visualisation were done using ClusterProfiler31, pathview32 and topGO 105 











Raw and processed data is accessible at the Gene Expression Omnibus (scRNA-seq: 107 
GSE154959 and bulk RNA-seq: GSE180169). We also provide data exploration through a 108 




Study design of mouse pulmonary EC single-cell transcriptomes in Control and PAH 113 
To study mouse ECs from healthy and PAH lungs, we used a Cdh5-CreERT2-TdTomato mouse 114 
line (Figure 1A), in which the EC-specific Cdh5-driven expression of TdTomato is inducible 115 
with tamoxifen and maintained in all ECs regardless of subsequent phenotypic changes. After 116 
a two-week tamoxifen wash-out period, TdTomato+ cells from the lungs were isolated using 117 
flow cytometry (Supplementary Figure S1). We designed two scRNA-seq experiments, 118 
allowing the final characterisation of Control and PAH TdTomato-positive cells with three 119 
replicates per conditions (Figure 1B). Experiment 1 aimed to assess the TdTomato+ cell-120 
sorting approach and analyse TdTomato+ cells from two Control lungs, ContA and ContB 121 
(Figure 1B). Experiment 2 was performed next and included three PAH samples (PAH1, 122 
PAH2, PAH3) and one Control (Cont1), kept in normoxic condition (Figure 1B). PAH was 123 
induced by exposing the Cdh5-CreERT2-TdTomato mice to chronic hypoxia for three weeks, 124 
alongside weekly injections of SU5416. We also performed bulk RNA-seq on TdTomato+ cells 125 
from 5 normoxic mice (bCont1-5) and 4 SuHx mice (bPAH1-4) to validate our scRNA-seq 126 
findings, and collected lung tissues from C57BL/6 mice in Control and SuHx conditions. We 127 
confirmed a significant increase in RVSP and right ventricular hypertrophy in PAH compared 128 
with Control mice for both the Cdh5-CreERT2-TdTomato and C57BL/6 lines (Supplementary 129 
Figure S2A) and a significant increase in the proportion of fully remodelled vessels in PAH 130 











From Experiment 1, we obtained an average of 3,621 cells per mouse with an average 100,273 132 
reads per cell using 10X Genomics scRNA-seq (Supplementary Figure S3A). Visualisation 133 
based on dimensionality reduction using Uniform Manifold Approximation and Projection 134 
(UMAP) and clustering revealed the presence of several cellular subpopulations comprising of 135 
cells from both mice, showing reproducibility between the two biological samples 136 
(Supplementary Figure S3B). Three main clusters out of five, corresponding to 88 % of the 137 
cells, had high TdTomato expression, confirming the quality of our TdTomato cell-sorting 138 
strategy (Supplementary Figure S3B). 139 
For Experiment 2, we obtained between 3,162 and 6,310 cells per mouse with an average of 140 
127,892 mean reads per cell (Supplementary Figure S4).  141 
 142 
PAH-induced lung EC transcriptome  143 
Samples from Experiment 1 and 2 were merged, allowing the comparison of three biological 144 
replicates per condition (PAH/Cont). UMAP visualisation and clustering analysis revealed a 145 
clear separation between PAH and Control cells (Figure 1C), suggesting a distinct PAH-146 
induced EC transcriptomic profile. These data also showed Control replicates overlapping 147 
within the same clusters (Figure 1C), despite the independent experimental process and 148 
sequencing. TdTomato expression analysis confirmed that most clusters (cluster 0, 1, 2, 3, 5 149 
and 7), which correspond to the majority of cells (95.5%) (Supplementary Figure S5A), showed 150 
high TdTomato expression (Figure 1C-D). These clusters also showed high expression of the 151 
pan-endothelial markers Cdh5 (Figure 1D) and Pecam1 (Supplementary Figure S5B). There 152 
was low TdTomato expression in clusters 4 and 6 (Figure 1D), which correspond to only 0.5% 153 
of the sequenced cells (Supplementary Figure S5A). Marker analysis for these two clusters 154 











suggesting that these were non-EC contaminants (Figure 1D, Supplementary Figure S5C). To 156 
confirm the identity of these cells, we use the tool SingleR which infers cell identities using 157 
transcriptomic data from pure cell type populations30. As expected, 96% of cells (24,333 out 158 
of 25,357) were annotated as ECs while cluster 4 contained immune cells and cluster 6 had a 159 
high proportion of fibroblasts (Figure 1E). This analysis confirmed the high recovery of ECs, 160 
with minimal contamination from other cell types, and suggested global maintenance of EC 161 
identity in normoxic and PAH-induced conditions. 162 
 163 
Limited endothelial to mesenchymal transition in Control and PAH lungs 164 
As EndMT has previously been reported in PAH 11-13, we investigated the potential presence 165 
of such a population in the scRNA-seq dataset. We could not detect cell populations with high 166 
TdTomato expression coupled with low endothelial marker (Cdh5 and Pecam1) expression 167 
(Figure 1C, 1D, Supplementary Figure S6A) or expression of mesenchymal markers (Acta2 168 
and Col1a1) (Supplementary Figure S6B). We also assessed the expression profiles of several 169 
EndMT regulators (Snai1, Snai2 and Smad3), but did not identify cell populations distinctly 170 
expressing these markers (Supplementary Figure S6C). To further investigate the presence of 171 
cells undergoing EndMT, we evaluated the percentage of Acta2+ cells within TdTomato+ cells 172 
in the different samples. Less than 1% of TdTomato+ cells expressed Acta2 in both Control 173 
and PAH (Supplementary Figure S6D). Similar profiles were found when considering Col1a1+ 174 
cells (Supplementary Figure S6E). We could not confirm the EndMT status of the Acta2+ cells, 175 
as they did not show increased expression of the mesenchymal marker Col1a1 and had 176 
comparable EC marker Cdh5 expression compared to Acta2- cells (Supplementary Figure 177 
S6F). This suggests that Acta2+ TdTomato+ cells are minimal in the lung and do not seem to 178 












Identification of pulmonary ECs subpopulations 181 
To further characterise the distinct EC populations in PAH and Control mice, we analysed only 182 
cells defined as “endothelial cells” by SingleR. UMAP reduction and clustering of the merged 183 
Control samples suggested inter-individual variation, rather than cell type-specific clustering 184 
(Supplementary Figure S7). Therefore, we used the Seurat integration tool to correct for batch 185 
effects, which resulted in 7 clusters for the merged Control samples (Figure 2A, Supplementary 186 
Table S1). EC subpopulation identification was based on canonical markers and guided by 187 
three recent scRNA-seq of lung ECs16, 34, 35. As expected, most ECs (around 70%) belong to a 188 
cluster identified as capillary (CapillaryA) (Figure 2B), based on Nrp1 and Sema3c enrichment 189 
(Figure 2C-D). We identified a second capillary cluster, herein defined as CapillaryB, 190 
characterised by Car4 expression, as described previously16, 34, 35. Two clusters expressed large 191 
vessel markers (Vwf and Vcam1) and were defined as venous (higher expression of Vwf and 192 
specific expression of Prss23) or arterial ECs (specific expression of Cxcl12 and Mgp) (Figure 193 
2C-D). An EC subpopulation with enriched expression of lymphatic EC markers Ccl21a and 194 
Prox1 was defined as “Lymphatic”. Additionally, we observed a small cluster with high cell 195 
cycle-related gene expression, here defined as “Proliferating”, and a second small cluster (< 196 
0.4% of cells) defined as “Sftp+”, with high surfactant protein gene (Sftpa1, Sftpb, Sftpc and 197 
Sftpd) expression (Figure 2C-D). Similar analysis of PAH samples detected the same 7 clusters 198 
(Supplementary Figure S8). 199 
 200 
EC subpopulation responses in PAH 201 
To define the transcriptional changes mediated by PAH in EC subpopulations, we integrated 202 











Control and PAH were also identified in this integrated analysis (Figure 3A-B). PAH samples 204 
showed a slightly higher proportion of Vein ECs compared to Control samples and similar 205 
proportion of the 4 other vessel type-specific ECs (i.e. Artery, CapillaryA, CapillaryB and 206 
Lymphatic ECs) (Figure 3C). The relative proportion of proliferative ECs was constant 207 
between Control and PAH lungs (Figure 3C). As human PAH is often associated with increased 208 
EC proliferation5, 7, we also assessed the percentage of cells in each cell cycle phase in each 209 
individual cluster and across all ECs but did not detect any significant differences between 210 
PAH and Control (Supplementary Figure S9), suggesting that the proportion of proliferating 211 
ECs is not increased at this stage of the SuHx model. 212 
We performed a differential gene expression analysis in each of the vessel type-specific EC 213 
clusters to identify PAH-dependent changes. Global and vessel-type specific changes were 214 
identified with a total of 222 significant differentially expressed genes (DEGs) detected, based 215 
on a log fold change of 0.25 (Figure 3D, Supplementary Table S2). This analysis revealed a 216 
greater number of DEGs in Artery, CapillaryA and CapillaryB ECs compared to Vein and 217 
Lymphatic ECs (Figure 3D). Some DEGs were commonly regulated in Artery, CapillaryA and 218 
Vein ECs, while CapillaryB and Lymphatic ECs exhibited subpopulation-specific 219 
transcriptomic responses to PAH (Figure 3D-E). For each EC subpopulation, we assessed the 220 
expression of the DEGs across the 3 Control and 3 PAH biological replicates and confirmed 221 
comparable responses across all replicates (Supplementary Figure S10). We also validated the 222 
changes of 42 genes (out of the 222 DEGs) in additional replicates using the bulk RNA-seq 223 
dataset (Supplementary Figure S11A). PCA analysis of the bulk RNA-seq confirmed the 224 
distinct profiles of the Control and PAH samples (Supplementary Figure S11B) and differential 225 
gene expression analysis identified 345 and 689 significant up- and down-regulated genes 226 
respectively, based on a 1.5-fold change (Supplementary Table S3). As bulk RNA-seq averages 227 











populations from the scRNA-seq. Delimiting our scRNA-seq analysis to a 1.5-fold change 229 
threshold in CapillaryA, 56% of DEGs could be validated in the bulk RNA-seq data 230 
(Supplementary Figure S11A).    231 
In addition to the vessel type EC clusters, we also analysed DEGs in the Proliferating EC 232 
clusters in PAH and Control. From the 42 significantly regulated genes (35 up-regulated, 7 233 
down-regulated), 36 genes were also differentially expressed in the vessel type EC clusters 234 
(Supplementary Figure S12A), suggesting that Proliferating ECs did not show a PAH-specific 235 
transcriptional response.   236 
In the scRNA-seq dataset, we also noticed 10 genes displaying upregulation in PAH1 and 237 
PAH3 but not PAH2 (Supplementary Figure S13A). Four of these genes were previously 238 
reported as downstream targets of the transcription factor AhR36, 37, which is activated by 239 
SU541638, suggesting that PAH2 had a limited response to SU5416 treatment. However, up-240 
regulation of six genes was validated in the bulk RNA-seq data (Supplementary Figure S13B), 241 
confirming their relevance to the SuHx model. 242 
To address inter-individual variability and identify high confidence candidates, we performed 243 
a stringent analysis of the scRNA-seq dataset. By comparing all individual PAH to all Controls 244 
samples and focusing on common changes, we obtained a list of 30 DEGs (Supplementary 245 
Figure S14, Supplementary Table S2). The lower number of cells in each comparison had less 246 
power to identify significant genes, hence the shorter DEG list, but this stringent approach gave 247 
priority to candidates with high and consistent changes. We confirmed the dysregulation of 14 248 
genes in the bulk RNA-seq (Supplementary Table S3).  249 
 250 











To understand the functional effects of these transcriptional changes, we performed a KEGG 252 
pathway enrichment analysis with the 222 DEGs identified in the group analysis (Figure 3D). 253 
The antigen processing and presentation pathway, involved in T-cell recruitment and 254 
activation39, was enriched across all vessel type ECs (Figure 4A) and Proliferating cells 255 
(Supplementary Figure S12B).  Seventeen genes from distinct segments of this pathway were 256 
up-regulated in Artery ECs in PAH (Figure 4B). The highest upregulation was observed for 257 
the major histocompatibility complex class II (MHC-II) and its chaperone, Cd74, in Artery and 258 
CapillaryA ECs (Figure 4C). However, the Cd80 and Cd86 co-stimulatory molecules required 259 
for naïve T-cell activation39 showed low expression in both Control and PAH (Figure 4C). The 260 
up-regulation of genes relevant to the antigen processing and presentation pathway was 261 
confirmed in the bulk RNA-seq (Figure 4D).  262 
 263 
PAH regulation of apoptosis, pro-migratory and pro-angiogenic genes in CapillaryB ECs  264 
To identify PAH-mediated gene up-regulation specific to CapillaryB ECs, we performed a 265 
hierarchical clustering of all CapillaryB DEGs based on their expression profiles across all EC 266 
subpopulations and conditions, and focussed on 37 genes showing a stronger response to PAH 267 
in CapillaryB (Figure 5A). Gene Ontology analysis revealed that these genes are involved in 268 
the regulation of localisation and cell death (Figure 5B-C).  EC cell death has been observed in 269 
early-stage PAH, with a peak of apoptotic cells detected at 1 week in the SuHx mouse model, 270 
followed by a longitudinal decrease5. Therefore, increased apoptotic cell numbers is not 271 
expected in the current study. Additionally, as the cell preparation for scRNA-seq includes a 272 
live cell selection, apoptotic cells, specifically late apoptotic cells, might not be represented in 273 
the scRNA-seq dataset. We did not observe a difference in the number of cells with high 274 











control and filtering (Supplementary Figure S3A, S4), suggesting apoptotic cells might not be 276 
associated with this stage of PAH. However, as changes in apoptotic regulatory genes may still 277 
be detectable, we analysed the signature score of genes involved in the execution of apoptosis 278 
(based on Gene Ontology GO:0097194) and positive and negative regulation of apoptosis (Go 279 
terms GO:0043065 and GO:0043066). While the expression of the execution phase of 280 
apoptosis genes was negligible across all EC types and condition (Supplementary Figure 281 
S15A), we observed an increase in expression of both positive and negative apoptotic 282 
regulatory genes in PAH (Supplementary Figure S15B), likely reflecting the ongoing 283 
regulation of apoptosis following the 1-week peak. We noted the significant up-regulation of 284 
the pro-apoptotic regulator Bax in CapillaryB in PAH (Figure 5D). 285 
Among the 37 genes with CapillaryB-specific changes, we also noticed the presence of three 286 
known tip cell-enriched genes: Cd34, Plasminogen Activator Urokinase Receptor (Plaur) and 287 
Apelin (Apln). Tip cells are localised at the tips of growing vessels during sprouting 288 
angiogenesis 40, 41 and are characterised by the expression of Dll4, Angpt2, Cxcr4, Apln 42, 43. 289 
We assessed the expression of these markers in the scRNA-seq but a tip cell subpopulation 290 
could not be identified (Supplementary Figure S16A) and only Apln was enriched in CapillaryB 291 
ECs (Figure 5C, Supplementary Figure S16A). In agreement with a lack of tip cells, the 292 
expression of genes involved in sprouting angiogenesis (GO:0002040) was negligible across 293 
EC subpopulations and conditions (Supplementary Figure S16B). In contrast, we observed a 294 
higher gene expression for positive, but not negative, regulators of angiogenesis (GO:0045766 295 
and GO:0016525) in CapillaryB ECs, with the PAH group having a higher expression than 296 
Control (Supplementary Figure S16C). These data suggest angiogenic regulatory pathways are 297 
activated in CapillaryB ECs and enhanced in PAH. Interestingly, 10 out of the 37 CapillaryB-298 











Table S1), suggesting that characteristics of CapillaryB ECs were enhanced in response to 300 
PAH.  301 
Overall, we showed PAH-mediated regulation of apoptotic, pro-migratory and pro-angiogenic 302 
genes in CapillaryB ECs.  303 
 304 
Relevance of PAH-mediated mouse EC changes in rat and human PAH  305 
To evaluate the relevance of the SuHx mouse scRNA-seq data in human PAH, we examined 306 
whether the expression of human genes with PAH-associated variants were also altered in 307 
mouse PAH ECs. From the 12 high-confidence genetic drivers of PAH3, 4 genes were 308 
identified: Aquaporin (Aqp1), Caveolin1 (Cav1), Bone Morphogenetic Protein Receptor Type 309 
2 (Bmpr2) and Endoglin (Eng). Aqp1, with the highest fold change and part of the stringent 310 
DEG set, was up-regulated in Artery, Vein, CapillaryA and Lymphatic ECs (Figure 6A). Cav1 311 
was also up-regulated while Bmpr2 and Eng were down-regulated (Figure 6A).  312 
We also mined recent rat21 and human PAH22 whole-lung scRNA-seq datasets. The rat dataset 313 
includes two different models of PAH: SuHx and monocrotaline (MCT). We retrieved data 314 
corresponding to the 758 annotated ECs, ranging from 1 to 343 per sample (Supplementary 315 
Figure S17A). Due to the low number of rat ECs, we integrated the rat with the mouse EC 316 
dataset, and obtained 7 EC subpopulations, per the mouse analysis (Supplementary Figure 317 
S17B-D). Rat Control, SuHx, and MCT ECs were present in all 7 clusters (Supplementary 318 
Figure S17D) and expressed similar EC subpopulation markers as the mouse ECs 319 
(Supplementary Figure S17E). The human dataset, which included 6 Controls and 3 IPAH 320 
samples, was analysed similarly to the mouse dataset starting from the raw sequencing data. 321 
After dimensional reduction and clustering, cluster 3 was annotated as ECs based on the 322 











We identified 3950 ECs (45 to 1137 per sample) across Control and IPAH (Supplementary 324 
Figure S18D). To identify EC subpopulations, we selected all ECs and performed a new 325 
dimensional reduction and clustering analysis after sample integration to take sample variation 326 
into account. We obtained 7 clusters, 5 of which correspond to different vessel types (Artery, 327 
Vein, CapillaryA, CapillaryB, and Lymphatic), and also identified bronchial ECs, as previously 328 
described in lung scRNA-seq44, and 3 minor clusters, not annotated in this study. 329 
To compare PAH-induced EC response across species, we performed a differential expression 330 
analysis between PAH and Control in the rat and human data for the four blood vessel type EC 331 
subpopulations (Artery, Vein, CapillaryA and CapillaryB). We obtained 991 DEGs in human 332 
ECs using the same threshold per the mouse analysis (Supplementary Table S4). We identified 333 
884 DEGs in rat ECs with a similar analysis but without multiple comparison corrections as 334 
the number of ECs was low in the different clusters and conditions (Supplementary Table S5). 335 
Overall, we found that 51% of the up-regulated mouse genes (14% of the mouse down-336 
regulated genes) were also differentially expressed in rat or human, and found 20 genes 337 
commonly regulated across all three species (Figure 6B). As Artery and CapillaryA ECs have 338 
a high number of up-regulated genes in mouse PAH, we analysed the DEG overlap in these 339 
two EC subpopulations (Supplementary Figure S19). Interestingly, three (Cd74, Sparc, Slc6a6) 340 
and five (Sparc, Cd81, Anxa2, Id3, Slc9a3r2) genes were up-regulated in mouse, rat and human 341 
Artery and CapillaryA ECs respectively (Supplementary Figure S19). In addition to CD74, 342 
genes in the MHC-II complex (HLA genes) were also up-regulated in human IPAH, suggesting 343 
the importance of this pathway (Figure 6C, Supplementary Figure S19). Several genes, 344 
including Adam15 and Sgk1, were up-regulated in all species but with some differences in the 345 
expressing EC subpopulation (Figure 6C, Supplementary Figure S19), likely reflecting species-346 
specific regulation or variability in categorising artery, vein and capillary EC clusters within 347 











in rat ECs (Supplementary Figure S17F), in agreement with a regulation by SU5416. Finally, 349 
five genes showing CapillaryB specificity in mouse were also up-regulated in human 350 
CapillaryB ECs in PAH, with APLN, CD31 and MYL6 specifically enriched in this 351 
subpopulation in human (Figure 6C).  352 
To determine functional relevance of the identified targets, we selected CD74 for its global 353 
alteration across mouse vessel type ECs in PAH and its regulation in rat and human datasets. 354 
Increased CD74 protein levels in IPAH ECs were previously reported from immunostaining of 355 
human IPAH tissues and western blot of isolated IPAH ECs45. Additionally, CD74 contributed 356 
to the recruitment of peripheral blood mononuclear cells to pulmonary ECs in vitro45, 357 
supporting the involvement of the CD74/MHC-II complex in PAH. As CD74 also affects cell 358 
proliferation in other cell types, including epithelial cells 46, we aimed to further characterise 359 
the role of CD74 via gene knockdown in human umbilical vein endothelial cells (HUVEC) 360 
(Figure 6D). CD74 depletion led to a decrease in EC proliferation measured by EdU 361 
incorporation (Figure 6E, Supplementary Figure S20A), and a loss of barrier resistance 362 
(Supplementary Figure S20B), specifically cell-cell interaction (Figure 6F) but not cell-matrix 363 
interaction (Supplementary Figure S20C). These data support the important contribution of 364 
CD74 to EC function.  365 
 366 
Mapping transcriptomic changes across the arteriovenous axis in PAH 367 
From the UMAP visualisation shown in Figure 3A, we observed Artery and Vein EC clusters 368 
attached to either side of the CapillaryA EC cluster, recapitulating the continuous lung vascular 369 
architecture. To study EC zonation across the arteriovenous axis, we performed an in silico 370 
lineage-tracing analysis using Slingshot33. Cells were ordered along the arteriovenous axis 371 











Cxcl12 respectively, were used to confirm a gradient of expression along the vasculature 373 
(Figure 7B). Control and PAH ECs were found across the arteriovenous axis, with slight 374 
differences in their distribution (Figure 7C). PAH cells were less distributed in large arteries 375 
and in the arterial side of the microvasculature (Figure 7C). This observation might reflect the 376 
enlarged arterioles and loss of distal vessels which are characteristic of PAH4. We carried out 377 
a stringent differential gene expression analysis in 10 sections along this axis, identifying 33 378 
DEGs, with a lower number of DEGs in the venous region of the axis (Figure 7D). This analysis 379 
revealed zonation-dependent changes (Figure 7E) with the Serum/Glucorticoid Regulated 380 
Kinase 1 (Sgk1) and Cd34 genes displaying a peak of upregulation at the junction between 381 
capillary and arterial ECs (Figure 7E-F). Two genes from the SPARC (secreted protein acidic 382 
and rich in cysteine) family of proteins also showed different expression profiles, with Sparc 383 
up-regulated in ECs from arteries and Sparcl1 up-regulated in the microvasculature (Figure 384 




To characterise PAH-induced EC molecular changes at the single-cell level, we performed 389 
scRNA-seq analysis across 3 SuHx-mediated PAH and 3 Control mice. Sorted EC sequencing 390 
enabled high resolution identification of PAH-induced EC responses at a subpopulation level 391 
and across the arteriovenous zonation. We showed the strong activation of the MHC-II pathway 392 
in Artery and CapillaryA ECs and the specific upregulation of pro-migratory and pro-393 
angiogenic genes in CapillaryB ECs in PAH. By comparing with rat and human genetic and 394 
transcriptomic data, we demonstrated the relevance of this mouse data across models and to 395 
human disease. We also identified promising and novel candidates regulated in ECs in PAH, 396 











in vitro. We also developed a web-based application for interactive exploration of this scRNA-398 
seq data (http://bakergroup.shinyapps.io/mouse_ec_pah). 399 
Using the Cdh5-CreERT2-TdTomato mouse line, we identified five main EC clusters 400 
corresponding to the different lung vessel types (Artery, Vein, CapillaryA, CapillaryB and 401 
Lymphatic), previously identified with different EC isolation strategies based on the surface 402 
markers CD3116, 34 or ICAM235. Interestingly, our analysis of publicly available rat21 and 403 
human22 PAH scRNA-seq datasets also revealed the presence of these 5 distinct subpopulations 404 
in rat and human PAH lung tissues. In mouse, we also identified two additional small clusters 405 
annotated as “Proliferating” and “Sftp+”. Proliferating ECs are sometimes found in healthy 406 
tissues at a low level16, 35, while “Sftp+” cluster corresponded to cells expressing high level of 407 
surfactant protein genes. As Sftp genes are highly expressed in alveolar type 2 cells (AT2)47, 408 
further work is required to determine if these cells are AT2 contaminants or a novel EC subtype. 409 
No major changes in cell population proportions were observed between Control and PAH 410 
mice. We noted a slight increase in the relative proportion of vein ECs in PAH. While this 411 
could indicate an absolute increase of vein ECs, this change could also reflect pruning of the 412 
distal vasculature leading to a change in the relative proportion of vein ECs if other vessel types 413 
regressed. Rat and human EC analysis also showed similar EC population proportions between 414 
PAH and Control samples, suggesting persistence of cell type identity and relative numbers, 415 
but with associated transcriptional changes. While late-stage PAH has previously been 416 
associated with EC proliferation7, the scRNA-seq suggest that EC proliferation is not evident 417 
at this time point in the SuHx model of PAH. 418 
The use of the mouse Cdh5-CreERT2-TdTomato line allowed us to assess the contribution of 419 
endothelial to mesenchymal transition in Control and PAH lungs. We did not identify any cell 420 











regulators. In our initial clustering, two small clusters showed non-EC marker expression. 422 
However, these two clusters also showed a low level of TdTomato expression, suggesting the 423 
presence of contaminants rather than transitioned ECs. The low proportion of 424 
TdTomato+/Acta2+ cells in both Control and PAH samples also suggests a minimal 425 
contribution of EndMT at this stage of PAH. Previous studies have shown the presence of 426 
EndMT in the SuHx mouse model using immunofluorescence and flow cytometry13. These 427 
differences could be explained by the sensitivity limitations of 10X Genomics scRNA-seq 428 
technology for low expressed genes and/or the transient and reversible nature of EndMT, which 429 
has been confirmed in recent scRNA-seq of ECs after myocardial infarction48. Further studies 430 
combining diverse detection methods and different pathological models across time points are 431 
required to confirm the contribution of EndMT in PAH at different stages of the disease.  432 
Our joint analysis of Control and PAH, combining three animals per group, revealed 222 DEGs 433 
across the 5 vessel type EC clusters. Overall, we found high reproducibility across replicates 434 
even when integrating two independent experiments, and confirmed the regulation of many 435 
candidates in additional mouse samples using bulk RNA-seq.  DEGs showing inter-individual 436 
differences in PAH mouse scRNA-seq included four direct targets of the transcription factor 437 
AhR36, 37 such as Cyp1a1 and Cyp1b1, up-regulated in PAH1 and PAH3 but not PAH2. In the 438 
rat SuHx model, SU5416 may exacerbate PAH through the activation of AhR38, suggesting 439 
that PAH2 had a reduced response to SU5416 treatment. All three PAH mice showed 440 
comparable RVSP and right ventricular hypertrophy, indicating that the AhR pathway is not 441 
necessary to induce PAH but may contribute to PAH progression. In agreement, Cyp1a1 and 442 
Cyp1b1 were found up-regulated in the rat SuHx scRNA-seq data but not in the MCT model 443 
nor in the human IPAH samples. Further work, including a larger mouse cohort and more in-444 
depth phenotypic characterisation, is required to dissect the contribution of SU5416 versus 445 











The largest change in PAH was the upregulation of MHC-II genes, affecting all ECs and 447 
particularly Artery and CapillaryA ECs (Figure 4). MHC-II genes are expressed by 448 
professional antigen-presenting cells39 and ECs under inflammatory conditions49. Our data 449 
suggests that this activation occurs in PAH. We did not detect the up-regulation of MHC-II co-450 
stimulatory molecules such as Cd80 and Cd86, suggesting that in PAH, ECs can contribute to 451 
the activation of antigen-experienced T-cells50, or to T-cell adhesion51, but not to the activation 452 
of naïve T-cells. In human studies, single-nucleotide polymorphisms and allele frequency of 453 
the MHC-II genes, HLA-DPA1 and HLA-DPB1, have been associated with PAH52. The effects 454 
of these variants on the pulmonary vasculature warrant further investigation.  455 
In contrast to the pan EC DEGs, we identified a CapillaryB-specific response to PAH, 456 
consisting of the up-regulation of many genes involved in cell localisation, negative regulation 457 
of cell death and angiogenesis. However, no apoptotic cells could be identified in the dataset, 458 
suggesting that apoptosis is not occurring at this stage in the SuHx model, in agreement with a 459 
peak of EC apoptosis occurring earlier, at 7 days5. We revealed the CapillaryB-specific 460 
regulation of tip cell-enriched genes Apln and Cd3440, 41 in both the mouse and human data, but 461 
without the detection of genuine tip cells. Interestingly, vessel regression, which is thought to 462 
be associated with dysfunctional sprouting angiogenesis in PAH4, can occur via different 463 
processes, including intussusceptive angiogenesis53 or EC migration involving a tip cell 464 
phenotype as seen in zebrafish54. More work is required to determine if any of these processes 465 
occur in PAH34.  466 
We analysed zonation-dependent changes across the arteriovenous axis in PAH, confirming 467 
the continuum of transcriptional states, as previously described for brain ECs19. The 468 
comparison between PAH and Control samples revealed specific gene regulation in distinct 469 
regions of the axis. In particular, Sgk1 showed an up-regulation in ECs corresponding to 470 











neomuscularization in PAH7. Since Sgk1 regulates angiogenesis55 and Sgk1 deficiency 472 
prevents hypoxia-induced PAH in mice56, Sgk1 appears to be a key regulator of the primary 473 
changes occurring in ECs. Two extracellular matrix-associated protein in the SPARC family 474 
were also up-regulated, with a prominent up-regulation of Sparc in pre-capillary ECs and 475 
Sparcl1 in capillary ECs. Sparc contributes to angiogenesis, with both pro-angiogenic and anti-476 
angiogenic effect reported57 while Sparcl1 has recently been reported as a biomarker of 477 
maladaptive right ventricular remodelling in pulmonary hypertension58.  478 
To identify promising EC gene targets relevant to the human disease, we compared the mouse 479 
PAH scRNA-seq with human genetic3, and rat21 and human22 transcriptomic data. In addition 480 
to the down-regulation of Bmpr2 gene, the main genetic driver of PAH, we showed up-481 
regulation of Aqp1 in ECs in PAH. The Aqp1 knockout mouse has an attenuated response to 482 
hypoxia-induced PAH59, suggesting Aqp1 function in ECs contributes to PAH progression. Our 483 
transcriptomic comparison across models and species showed the relevance of this high-484 
resolution mouse EC PAH analysis and highlighted novel candidates to modulate EC 485 
dysfunction in PAH. The cross-species analysis was also essential to define gene targets 486 
differentially regulated across species and in early and late stages of the disease. However,  the 487 
human IPAH scRNA-seq22 analysis was limited by the small number of patient samples, 488 
preventing an analysis of patient variability. Future studies, including more human samples 489 
and additional time points in the rodent PAH models, are required to fully characterise PAH 490 
disease progression.   491 
Among the candidates conserved across species, we focussed on CD74, as an increase in EC 492 
CD74 protein level has previously been identified in human PAH samples45.  CD74 is a 493 
receptor for the macrophage migration inhibitory factor, and the CD74/MIH complex was 494 
associated with PAH and linked to the recruitment of leukocytes to ECs in-vitro45. The scRNA-495 











that the CD74/MHC-II complex might contribute to PAH progression. As multiple functions 497 
for CD74 have been reported46, we expanded the functional characterisation of CD74 in ECs 498 
and showed its role in barrier function as well as proliferation, suggesting a potential role of 499 
CD74 in the hyperproliferative EC phenotypes characteristics of late PAH. 500 
Overall, our study provides high resolution insights into the diversity of EC subpopulation 501 
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Figure legends: 745 
 746 
Figure 1: Single-cell RNA-seq of lung ECs in Control and PAH mice. 747 
A. Mouse breeding schema to produce the Cdh5-CreERT2-TdTomato line. 748 
B. Experimental timeline for Experiment 1 and 2. 749 
C. Uniform Manifold Approximation and Projection (UMAP) plot of the merged data. Colours 750 
represent cell clusters, samples and TdTomato expression, respectively. 751 
D. Violin plot of TdTomato, Cdh5, Tyrobp and Gsn expression in the defined clusters. 752 
E. UMAP plot of cell identity defined by the tool SingleR. 753 
 754 
Figure 2: Identification of EC subpopulations in integrated Control samples.  755 
A. UMAP plot of integrated Control samples. Colours represent annotated cell clusters and 756 
individual sample, respectively. 757 
B. Proportion of EC subpopulation in individual Control samples. 758 
C. Heatmap of the top 10 marker gene expression in a downsampling of 100 cells from each 759 
cluster. 760 
D. UMAP plot of representative markers expression in the different clusters. 761 
 762 
Figure 3: Differential gene expression analysis between PAH and Control in the vessel 763 
type EC populations. 764 
A. UMAP plot of integrated Control and PAH samples. Colours represent annotated cell 765 
clusters.  766 











C. Proportion of the annotated EC subpopulations in Control and PAH samples. Error bars 768 
correspond to standard error of the mean. P-value obtained using an unpaired t-test on the log10 769 
proportion (* p-value<0.05). 770 
D. Venn diagram of differential gene expression changes (number of up-regulated genes/ 771 
number of down regulated genes) in the 5 vessel type EC subpopulations.  772 
E. Heatmap of all differentially expressed genes across vessel type EC subpopulations and 773 
conditions in a downsampling of 50 cells per category. 774 
 775 
Figure 4: Activation of the antigen processing and presentation pathway in ECs in PAH. 776 
A. Top 3 enriched KEGG pathways for each vessel type DEG. 777 
B. Visualisation of the Artery DEGs on the “Antigen Processing and Presentation” pathway 778 
graph. 779 
C. Dot plot showing the expression of DEG annotated in the KEGG “Antigen Processing and 780 
Presentation” pathway and their co-stimulators across the EC subpopulations and conditions.  781 
D. Heatmap (z-score of Log2(FPKM+1) of significant genes involved in the Antigen 782 
Processing and Presentation pathway in the bulk RNA-seq of TdTomato+ cells. 783 
 784 
Figure 5: Characterisation of the PAH response in CapillaryB EC subpopulation. 785 
A. Heatmap of up-regulated genes in CapillaryB in a downsampling of 50 cells per category. 786 
A hierarchical clustering approach was used to identify genes with a specific up-regulation in 787 
CapillaryB compared to the other EC populations. 788 
B. Top 10 enriched Go Terms (Biological Process) of the CapillaryB-specific up-regulated 789 
genes. 790 
C. Dot plot showing the expression of genes specifically up-regulated in CapillaryB and 791 











D. Violin plot of Bax expression across EC populations and conditions. 793 
 794 
Figure 6:  Comparison of the mouse PAH DEGs with human genetics and transcriptomics 795 
data. 796 
A. Violin plot showing the expression of 4 DEGs with PAH-associated variants, across EC 797 
populations and conditions. 798 
B. Number of mouse up/down-regulated genes regulated in the same direction in rat or human 799 
PAH ECs. 800 
C. Dot plot showing the expression of selected candidates across EC populations and 801 
conditions in mouse and human scRNA-seq. 802 
D. Expression of CD74 in Control (siCT) and CD74 (siCD74) knockdown HUVECs by RT-803 
qPCR. RQ: Relative quantification normalized to UBC relative to siCT (n=4). 804 
E. Quantification of EdU uptake in siCT and siCD74 HUVECs (n=3). 805 
F. Cell-to cell interaction, expressed as Rb [Ohm x cm2], in siCT and siCD74 HUVECs across 806 
a 6h time course with bar graph showing the average across the time points (n=3). 807 
Graph in panel D, E and F correspond to mean ± standard error of the mean and p-values were 808 
obtained using an unpaired t-test. * p-value<0.05 and *** p-value<0.0001. 809 
  810 
Figure 7: Differential gene expression changes across the arteriovenous axis 811 
A. UMAP plot of Artery, CapillaryA and Vein selected clusters. Colours correspond to EC 812 
subpopulations and trajectory unit, respectively. Trajectory arbitrary unit corresponding to the 813 
arteriovenous axis unit and trajectory line were obtained with Slingshot.  814 
B. Expression of the vein marker Prss23, capillary marker Sema3c and artery marker Cxcl12 815 
in Control and PAH cells ordered along the arteriovenous axis. 816 











D. Differential gene expression changes in 10 distinct sections of the arteriovenous axis based 818 
on a stringent analysis of individual samples. 819 
E. Heatmap of the stringent DEG Log Fold change across 10 distinct sections of the 820 
arteriovenous axis.  821 
F. Expression profile across the arteriovenous axis in Control and PAH conditions for Sgk1, 822 
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